Using AI to diagnose and treat diseases in older adults

Application of AI Technology for the Diagnosis and Treatment of Geriatric Diseases

This study is testing how AI can help diagnose and treat diseases like Parkinson's and Alzheimer's in older adults by looking at things like handwriting and speech.

Quick facts

• Study type: Observational
• Enrollment: 460 (estimated)
• Ages: 8 Years to 100 Years
• Sex: All
• Sponsor: Qilu Hospital of Shandong University (other)
• Locations: 1 site (Jinan, Shandong)
• Trial ID: NCT06295263 on ClinicalTrials.gov

What this trial studies

This observational study aims to collect and analyze various characteristics such as handwriting, gait, speech, eye movements, and biological samples from patients with Parkinson's disease, Alzheimer's disease, and other neurological disorders, as well as healthy elderly and young controls. The study will utilize AI technology to correlate these markers with diagnostic and treatment plans. A total of 100 patients for each of the primary conditions and 80 healthy controls will be enrolled to gather comprehensive data for analysis.

Who should consider this trial

Good fit: Ideal candidates include patients diagnosed with Parkinson's disease, Alzheimer's disease, or other neurological disorders, as well as healthy elderly and young individuals for comparison.

Not a fit: Patients with severe mental illness who are unable to cooperate or those not meeting the specific diagnostic criteria for the included conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the accuracy of diagnosing and treating geriatric diseases using advanced AI technology.

How similar studies have performed: Other studies have shown promise in using AI for diagnosing neurological conditions, but this specific approach focusing on geriatric diseases is relatively novel.

Eligibility criteria

1. Inclusion Criteria 1.1 A total of 100 patients with primary Parkinson's disease were enrolled. The inclusion criteria were as follows: patients with primary Parkinson's disease, based on the 2015 MDS diagnostic criteria for Parkinson's disease. Disorder (MMSE score \< 24); (3) those with severe mental illness who are difficult to cooperate.

   1.2 A total of 100 patients with Alzheimer's disease were enrolled. The inclusion criteria were as follows: patients with Alzheimer's disease, based on the IWG-2 clinical diagnostic criteria.

   1.3 Neurodegenerative diseases (non-PD and non-AD) group (n = 100) : meeting the diagnostic criteria of the corresponding diseases.

   1.4 Eighty healthy elderly controls were included. The inclusion criteria were as follows: ① voluntarily participated in this study and signed the informed consent; ② Age and gender were matched with the case group.

   1.5 80 young healthy controls, inclusion criteria: ① voluntarily participated in this study and signed the informed consent; ② Gender was matched with the case group, and the age was less than 60 years old.
2. Exclusion Criteria 2.1 A total of 100 patients with PD were enrolled. Exclusion criteria: ① patients with other central nervous system diseases, such as cerebrovascular diseases, brain trauma, inflammatory diseases of the central system, intracranial tumors and after neurosurgery; ② patients with various types of cognitive impairment (MMSE score \< 24); (3) those with severe mental illness who are difficult to cooperate.

2.2 A total of 100 patients with Alzheimer's disease were enrolled. The exclusion criteria were: ① patients with other central nervous system diseases, such as cerebrovascular diseases, brain trauma, central system inflammatory diseases, intracranial tumors and after neurosurgery; ② patients with severe mental illness who are difficult to cooperate.

2.3 Neurodegenerative diseases (non-PD non-AD) group (n = 100), exclusion criteria: ① patients with other central nervous system diseases, such as cerebrovascular diseases, brain trauma, central system inflammatory diseases, intracranial tumors and after neurosurgery; ② patients with severe mental illness who are difficult to cooperate.

2.4 Eighty healthy elderly controls were included. The exclusion criteria were as follows: ① History of chronic diseases related to the study subjects, such as cerebrovascular diseases, brain trauma, inflammatory diseases of the central system, intracranial tumors and neurosurgery; ② patients with various types of cognitive impairment (MMSE score \< 24); ③ Poor compliance.

2.5 80 young healthy controls, exclusion criteria: ① history of chronic diseases related to the study subjects, such as cerebrovascular diseases, brain trauma, inflammatory diseases of the central system, intracranial tumors and neurosurgical surgery; ② patients with various types of cognitive impairment (MMSE score \< 24); ③ Poor compliance.

Where this trial is running

Jinan, Shandong

• Qilu Hospital of Shandong University — Jinan, Shandong, China (RECRUITING)

Study contacts

• Study coordinator: Jun Ma

Conditions: Parkinson Disease, Alzheimer Disease, Nervous System Diseases, Geriatric Diseases, geriatric diseases, AI, Deep learning